Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. - Wikidata - wikimedia - TriplyDB

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

http://www.wikidata.org/entity/Q45848130

about

Purinergic signalling and cancer CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview Ecto-5'-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration The roles of CD73 in cancer Ticlopidine in its prodrug form is a selective inhibitor of human NTPDase1 Consequences of the lack of CD73 and prostatic acid phosphatase in the lymphoid organs.Chemotherapeutic drugs induce ATP release via caspase-gated pannexin-1 channels and a caspase/pannexin-1-independent mechanism.Graft-versus-host disease is enhanced by selective CD73 blockade in mice Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice.Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.CD73-generated adenosine is critical for immune regulation during Toxoplasma gondii infection.Purinergic signaling on leukocytes infiltrating the LPS-injured lung Pullulan: a new cytoadhesive for cell-mediated cartilage repair.CD73 Activity is Dispensable for the Polarization of M2 Macrophages.Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues CD73 promotes tumor growth and metastasis Host CD73 impairs anti-tumor immunity Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma.Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantation Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.Anti-CD73 in cancer immunotherapy: awakening new opportunities.Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma.CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors Role of CD73 in Renal Sympathetic Neurotransmission in the Mouse Kidney.Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread.Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future.Ectoenzymes controlling leukocyte traffic.ENTPD1/CD39 is a promising therapeutic target in oncology.Purinergic signalling in the lower urinary tract.CD73 and adenosine generation in the creation of regulatory microenvironments.Ectoenzymes in leukocyte migration and their therapeutic potential.Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.CD73-adenosine: a next-generation target in immuno-oncology.

P2860

Q24618782-E1FF3F02-DC8C-46C9-84BB-49FF7859736C Q26823709-C4B2579C-4920-4057-A350-13C0343EC797 Q27002950-0980589B-D37C-46C7-8D92-A8674E9E2C46 Q27312282-5A1A00D4-C0EA-44D2-AC07-E65FC982F856 Q28087576-8F6932FB-1CBF-4615-8A28-CC2F572DBB3E Q28250207-85236C5A-0500-4B08-B772-0ADF08326CD4 Q28550667-E7D5685E-CED0-4767-AF84-664F8D5D29DF Q34003164-3DF637D0-BF23-4578-9B1C-B3CB1867D6B7 Q34087391-40A66134-00C3-42D6-B485-8D07E8AA3EBF Q34153071-C21E42B0-5470-49CB-8F32-550F7F50B3B9 Q34245132-D1F3BB2D-C626-4D06-AC5D-8CF92B9E1962 Q34631798-2115AB49-5F9F-47F2-90B4-E4D7105E0068 Q34695338-A32A5FC8-8D5E-4738-9853-E905D5F212F3 Q34703746-0AC8B7D8-1263-4F96-A486-94BFCDF7E0CE Q34955749-B43C6565-C4F4-4EB1-AE89-ED2B206C0144 Q35153165-7F9CDD45-0872-4E56-9D46-15BB54AD0539 Q35552862-75DEC4DC-5C84-4D8B-B0A8-17FD0437954F Q35741497-0B524437-EE30-4E4C-A464-962490A14928 Q35973670-C5C4464E-6E27-4393-A28A-7CE72ECF3808 Q36038399-4BAC8D57-9B94-40B1-BBE5-3A040B4F159E Q36038421-830B8AD3-3CD9-4E77-9E0D-628EF4066037 Q36233927-FBBBF60F-906D-489D-A5D8-692C0EF9F155 Q36350059-0C768A0D-C4FA-456D-97CD-F493F682502C Q36430733-83A67D7C-1FA0-4315-8711-8957A235EB97 Q36709157-6273B5D9-B3C6-4158-9EDE-A8D8996A1365 Q36731173-6C6FA2D8-4EAD-4734-B55E-DF9A3C1DFA0E Q36991010-D480A0E6-FE7C-41A8-8056-32AF60FBAB01 Q37079141-EA70F820-018F-405A-A968-CC995E613B8C Q37157425-74DC86E9-B257-445D-8D1A-D816F9BDE661 Q37188515-494E5005-FD73-4927-850C-8C2C6D5BB3D7 Q37650141-ED3C242D-4FEC-4B93-B188-19747FC0E422 Q37868326-AE7D75BF-0496-4D76-BA17-CFE977418B7E Q37975129-ADC00C7E-8CD1-498A-B5BF-8FAE0194AE6C Q37987477-18FFE3E7-8E98-4FEB-83E5-306633F3BDE7 Q38023121-ADA2AE89-7EF5-4B6E-BDA5-72F5C040149A Q38061933-3613BEC8-FBBC-4CBD-BAD4-5D388DA2938D Q38063958-D3A1B6F2-0D7C-4E24-9FBA-CA52F02E913C Q38196724-1A0A7778-2615-476E-824A-9DE0E125EEF2 Q38209586-A5A561A8-2DC6-4B47-8CD7-73333886CD73 Q38711094-18375091-5754-45E0-9068-2BC66CF1E9FE

P2860

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

http://www.wikidata.org/entity/Q45848130

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

@en

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

@nl

type

label

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

@en

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

@nl

prefLabel

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

@en

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

@nl

P1433

Q45848130-EFDA35F3-DF98-44E6-8414-513C56571CFC

P1476

Q45848130-448AE3E0-17A3-4942-8D6B-173FF95388B0

P2093

Q45848130-325504DE-5A50-45EF-880A-D8C472F8B9CA

Q45848130-72943223-752C-481E-806E-0F36AA957294

Q45848130-76FC51F6-4870-4CBA-ACED-026108AB95D5

Q45848130-7B06CAAB-3E40-486B-8F60-5C2737D58E0C

Q45848130-86831CE4-88B2-4DCC-843F-6E8C09E09278

Q45848130-CB6F4B4F-D866-4ABB-9F12-4A884D12A930

Q45848130-EE3D2687-B478-4EA3-8054-6637CD6AAA39

P2860

Q45848130-0526E45B-19D3-4E35-861D-38F16C89E06E

Q45848130-0ED0E607-2DBA-4024-B98C-C1AD74D66D91

Q45848130-0F09677B-6A4A-432C-A294-7E390237F430

Q45848130-1DF412CE-867C-4C23-8B22-66AE9D3E5F64

Q45848130-1F03B1C6-EEE2-4C24-B230-EBDC4710664B

Q45848130-22978393-7CA2-49DF-9D98-283C417F6A48

Q45848130-2588D248-EE93-4183-9622-A6F15716FA08

Q45848130-2B9AA6D5-19BD-4313-ABB8-8737ED396B19

Q45848130-2D9C12D3-723D-407E-A960-5A2FC222AEC1

Q45848130-2ED1A619-C411-4A66-9B57-AF602ABBA724

P304

Q45848130-765F745D-3410-4CA7-9DF3-D2351C489B56

P31

Q45848130-88340556-0E73-40C0-8712-6D675BF0D288

P356

Q45848130-5F06CF0B-DA7F-4575-884A-192C016E5FF1

P407

Q45848130-9C3F1080-741A-4863-BBE8-95A4C26B1555

P433

Q45848130-61359743-67F4-41FE-AE6A-A349F6EEC77F

P478

Q45848130-C2B69DED-09D4-44E7-8383-F53126A895F8

P50

Q45848130-44732F1C-27E8-42B7-97CB-956CA2E4C076

P577

Q45848130-684CA507-96BB-4138-83B9-87E48753A1F1

P5875

Q45848130-96D9E722-307A-4D37-8B1A-81CD618F418C

P698

Q45848130-F74168BB-324F-474C-BA4A-FDDAF9CC37FC

P356

P1433

European Journal of Immunology

P1476

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.

@en

P2093

Fumiko Marttila-Ichihara

http://www.w3.org/2001/XMLSchema#string

Juha P Laurila

http://www.w3.org/2001/XMLSchema#string

Jussi Niemelä

http://www.w3.org/2001/XMLSchema#string

Kati Elima

http://www.w3.org/2001/XMLSchema#string

Marika Karikoski

http://www.w3.org/2001/XMLSchema#string

Marko Salmi

http://www.w3.org/2001/XMLSchema#string

Sirpa Jalkanen

http://www.w3.org/2001/XMLSchema#string

P2860

RanBPM associates with CD39 and modulates ecto-nucleotidase activity

CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73

Exploring the full spectrum of macrophage activation

Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia.

Ecto-enzyme and signaling functions of lymphocyte CD73

Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase

Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

Alternative activation of macrophages: mechanism and functions

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.

P304

1231-1241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJI.201041292

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Gennady Yegutkin

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51021541

http://www.w3.org/2001/XMLSchema#string

P698

21469131

http://www.w3.org/2001/XMLSchema#string